Nyheter | Spotlight

Press release from Companies

Publicerat: 2019-08-16 12:08:25

PolarCool: PolarCool AB (publ): additional data from the pilot study with SHL and HockeyAllsvenskan show further improved results from the concussion study with PolarCap® System

In collaboration with the Swedish Hockey League (SHL) and HockeyAllsvenskan, PolarCool conducted a study during the past three seasons, wherein PolarCap® System has been evaluated for the treatment of concussion. A total of 12 teams participated in the study; the intervention group has used the PolarCap® System and the control group has consisted of players who have not received the treatment.

The purpose of the clinical study has been to measure symptom relief, in order to examine how quickly the player progresses through a mandatory rehab program until return to play. The program is a rehabilitation process with progressively increased activity that lasts for at least 6 days, where the last step involves full participation in training or match (so-called Return To Play).

In April 2019, PolarCool published results from, till then, reported cases in the pilot study. As additional data has been received from the previous season and preliminarily analyzed, PolarCool can today announce that the updated result is so significant that the principal investigator of the study intends to make a scientific publication. The recently received data further strengthens the preliminary results that showed significant benefits of cooling. The complete results will be presented as soon as all the additional data from the previous season is obtained and analyzed. A scientific article is expected to be published in the first half of 2020. 

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on August 16, 2019. 


For more information

Iman Ziai – CEO                                          
+46 - 733 -99 23 17                                                                              
E-mail: iman.ziai@polarcool.se


Om PolarCool AB (publ)

PolarCool AB (publ) är ett medicinteknikföretag som utvecklar, marknadsför och säljer produkter inom idrottsmedicin. Bolaget fokuserar på behandling av hjärnskakning och upprepade huvudkollisioner. PolarCool AB (publ) har sitt säte i Lund. Aktien är noterad på Spotlight Stock Market. 

Läs mer hos Cision
Läs mer om PolarCool